SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
Nvidia Develops New Location-Verification Technology for AI Chips 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
SAN DIEGO, Nov. 08, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the company will participate in the Stifel 2017 Healthcare Conference in New York, NY.
The Company will be presenting at 9:30 AM Eastern on Wednesday, November 15, 2017. A live webcast of the presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
